<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33433869</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1281</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>76</EndPage><MedlinePgn>67-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-51140-1_5</ELocationID><Abstract><AbstractText>The identification of C9orf72 gene has led to important scientific progresses and has considerably changed our clinical practice. However, a decade after C9orf72 discovery, some important clinical questions remain unsolved. The reliable cutoff for the pathogenic repeat number and the implication of intermediate alleles in frontotemporal dementia, amyotrophic lateral sclerosis, or in other diseases are still uncertain. The occurrence of an anticipation phenomenon&#xa0;- at the clinical and molecular levels&#xa0;- in C9orf72 kindreds is still debated as well, and the factors driving age at onset and phenotype variability are largely unknown. All these questions have a significant impact not only in clinical practice for diagnosis and genetic counseling but also in a research context for the initiation of therapeutic trials. In this chapter, we will address all those issues and summarize the recent updates about clinical aspects of C9orf72 disease, focusing on both the common and the less typical phenotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle &#xe9;pini&#xe8;re (ICM), H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMMA, Centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France. isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle &#xe9;pini&#xe8;re (ICM), H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Sorbonne Universit&#xe9;, Paris, France. isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMMA, Centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France. isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICM-UMRS_1127, ICM, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris Cedex 13, France. isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Anticipation</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33433869</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-51140-1_5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC Hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72(2):245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">3202986</ArticleId><ArticleId IdType="pmc">3202986</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR et al (2011) A Hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72(2):257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pubmed">3200438</ArticleId><ArticleId IdType="pmc">3200438</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, Maletta RG et al (2014) Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Hum Mol Genet 23(21):5630&#x2013;5637</Citation><ArticleIdList><ArticleId IdType="pubmed">24908669</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddu279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 36(8):450&#x2013;459</Citation><ArticleIdList><ArticleId IdType="pubmed">23746459</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2013.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122(1):111&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pubmed">21644037</ArticleId><ArticleId IdType="pmc">3285143</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M (2020) Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol 139(1):83&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">31501924</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02070-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Troakes C, Maekawa S, Wijesekera L, Rogelj B, Sikl&#xf3;s L, Bell C et al (2012) An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline: p 62 proteinopathy. Neuropathology 32(5):505&#x2013;514</Citation><ArticleIdList><ArticleId IdType="pubmed">22181065</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1789.2011.01286.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 127(3):347&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">24356984</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S et al (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11(4):323&#x2013;330</Citation><ArticleIdList><ArticleId IdType="pubmed">22406228</ArticleId><ArticleId IdType="pmc">3322422</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T et al (2012) Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135(3):736&#x2013;750</Citation><ArticleIdList><ArticleId IdType="pubmed">22366791</ArticleId><ArticleId IdType="pmc">3286330</ArticleId><ArticleId IdType="doi">10.1093/brain/awr361</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boill&#xe9;e S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M et al (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49(4):258&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pubmed">22499346</ArticleId><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L et al (2019) Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol 19:145&#x2013;156. S1474442219303941</Citation><ArticleIdList><ArticleId IdType="pubmed">31810826</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(19)30394-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, He J, Gao F-B, Gitler AD, Fan D (2018 Aug) The epidemiology and genetics of amyotrophic lateral sclerosis in China. Brain Res 1693:121&#x2013;126</Citation><ArticleIdList><ArticleId IdType="pubmed">29501653</ArticleId><ArticleId IdType="pmc">6486791</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2018.02.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamim U, Ambawat S, Singh J, Thomas A, Pradeep-Chandra-Reddy C, Suroliya V et al (2020) C9orf72 hexanucleotide repeat expansion in Indian patients with ALS: a common founder and its geographical predilection. Neurobiol Aging 88:156.e1&#x2013;156.e9. S0197458019304531</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.12.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11(3):232&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pubmed">22305801</ArticleId><ArticleId IdType="pmc">3315021</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Guillot-Noel L, Hannequin D, Lacomblez L, Golfier V, Puel M et al (2013) C9ORF72 repeat expansions in the frontotemporal dementias Spectrum of diseases: a flow-chart for genetic testing. JADA 34(2):485&#x2013;499</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-121456</ArticleId></ArticleIdList></Reference><Reference><Citation>Solje E, Aaltokallio H, Koivumaa-Honkanen H, Suhonen NM, Moilanen V, Kiviharju A et al (2015) The phenotype of the C9ORF72 expansion carriers according to revised criteria for bvFTD. Dermaut B, editor. PLoS One 10(7):e0131817</Citation><ArticleIdList><ArticleId IdType="pubmed">26146826</ArticleId><ArticleId IdType="pmc">4493025</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0131817</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J et al (2020 Jan) Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a north American cohort. Alzheimers Dement 16(1):60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">31914226</ArticleId><ArticleId IdType="pmc">7192555</ArticleId><ArticleId IdType="doi">10.1002/alz.12046</ArticleId></ArticleIdList></Reference><Reference><Citation>Montembeault M, Sayah S, Rinaldi D, Le Toullec B, Bertrand A, Funkiewiez A et al (2020) Cognitive inhibition impairments in presymptomatic C9orf72 carriers. J Neurol Neurosurg Psychiatry 91:366&#x2013;372. jnnp-2019-322242</Citation><ArticleIdList><ArticleId IdType="pubmed">32054668</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-322242</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K, Convery R, Bocchetta M, Neason M, Cash DM, Greaves C et al (2020) A modified camel and Cactus test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Appl Neuropsychol Adult Feb 5:1&#x2013;38. Online ahead of print</Citation></Reference><Reference><Citation>Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O et al (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135(3):765&#x2013;783</Citation><ArticleIdList><ArticleId IdType="pubmed">22366793</ArticleId><ArticleId IdType="pmc">3286335</ArticleId><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId></ArticleIdList></Reference><Reference><Citation>Convery R, Mead S, Rohrer JD (2019) Review: clinical, genetic and neuroimaging features of frontotemporal dementia. Neuropathol Appl Neurobiol 45(1):6&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">30582889</ArticleId><ArticleId IdType="doi">10.1111/nan.12535</ArticleId><ArticleId IdType="pmc">30582889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Gordon E, Cardoso MJ, Modat M, Ourselin S, Warren JD et al (2018) Thalamic atrophy in frontotemporal dementia&#x2014;not just a C9orf72 problem. NeuroImage: Clinical 18:675&#x2013;681</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.02.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Ong E, Goh S-YM, Bajorek L, Dever R, Staffaroni AM et al (2020) Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement 16(1):49&#x2013;59</Citation><ArticleIdList><ArticleId IdType="pubmed">31784375</ArticleId><ArticleId IdType="pmc">6988137</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2019.08.196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Iglesias JE, Neason M, Cash DM, Warren JD, Rohrer JD (2020) Thalamic nuclei in frontotemporal dementia: Mediodorsal nucleus involvement is universal but pulvinar atrophy is unique to C9orf72. Hum Brain Mapp 41(4):1006&#x2013;1016</Citation><ArticleIdList><ArticleId IdType="pubmed">31696638</ArticleId><ArticleId IdType="doi">10.1002/hbm.24856</ArticleId><ArticleId IdType="pmc">31696638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B et al (2018) Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging 62:191&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">29172163</ArticleId><ArticleId IdType="pmc">5759893</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, Sha SJ, Rutherford NJ, Fong JC et al (2012) Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 83(4):358&#x2013;364</Citation><ArticleIdList><ArticleId IdType="pubmed">22399793</ArticleId><ArticleId IdType="pmc">3388906</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2011-301883</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Serrano S, de Toledo M, P&#xe9;rez-P&#xe9;rez J, Sainz MJ (2014) Familial benign frontotemporal deterioration with C9ORF72 hexanucleotide expansion. Alzheimers Dement 10:S284&#x2013;S289</Citation><ArticleIdList><ArticleId IdType="pubmed">24439166</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2013.09.013</ArticleId><ArticleId IdType="pmc">24439166</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhonen N-M, Kaivorinne A-L, Moilanen V, Bode M, Takalo R, H&#xe4;nninen T et al (2015) Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. Neurocase 21(1):85&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">24417314</ArticleId><ArticleId IdType="doi">10.1080/13554794.2013.873057</ArticleId><ArticleId IdType="pmc">24417314</ArticleId></ArticleIdList></Reference><Reference><Citation>Llamas-Velasco S, Garc&#xed;a-Redondo A, Herrero-San Mart&#xed;n A, Puertas Mart&#xed;n V, Gonz&#xe1;lez- S&#xe1;nchez M, P&#xe9;rez-Mart&#xed;nez DA et al (2018 Jan 2) Slowly progressive behavioral frontotemporal dementia with C9orf72 mutation. Case report and review of the literature. Neurocase 24(1):68&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">29355451</ArticleId><ArticleId IdType="doi">10.1080/13554794.2018.1428353</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente ES, Caramelli P, Gambogi LB, Mariano LI, Guimar&#xe3;es HC, Teixeira AL et al (2019) Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review. Alz Res Therapy 11(1):30</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0483-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher SA, Wong C, Pearson IE, Pal S. (2019) Survival and prognostic factors in C9orf72 repeat expansion carriers: a systematic review and meta-analysis. JAMA Neurol. [cited 2020 Feb 27]</Citation></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, D&#x2019;Ovidio F, Vasta R et al (2020) ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 94(8):e802&#x2013;e810</Citation><ArticleIdList><ArticleId IdType="pubmed">31907290</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH et al (2019) Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology</Citation></Reference><Reference><Citation>Chio A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C et al (2012) Extensive genetics of ALS: a population-based study in Italy. Neurology 79(19):1983&#x2013;1989</Citation><ArticleIdList><ArticleId IdType="pubmed">23100398</ArticleId><ArticleId IdType="pmc">3484987</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182735d36</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AMT et al (2012) Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135(3):693&#x2013;708</Citation><ArticleIdList><ArticleId IdType="pubmed">22300873</ArticleId><ArticleId IdType="pmc">3286329</ArticleId><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Ang LC, Jesso S, MacKinley J, Baker M, Brown P et al (2013) Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort. Cogn Behav Neurol 26(3):146&#x2013;154</Citation><ArticleIdList><ArticleId IdType="pubmed">24077574</ArticleId><ArticleId IdType="pmc">4090685</ArticleId><ArticleId IdType="doi">10.1097/WNN.0000000000000008</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D, Reif A, Dell&#x2019;Osso B, Kittel-Schneider S, Leonhard C, Herr A et al (2014) The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol Aging 35(5):1214.e7&#x2013;1214.e10</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW et al (2015) Clinicopathological study of patients with C9ORF72-associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol 28(2):99&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">25342578</ArticleId><ArticleId IdType="doi">10.1177/0891988714554710</ArticleId><ArticleId IdType="pmc">25342578</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR (2018) Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology 91:e1498&#x2013;e1507</Citation><ArticleIdList><ArticleId IdType="pubmed">30258023</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000006344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellami L, St-Onge F, Poulin S, Laforce R (2019) Schizophrenia phenotype preceding behavioral variant frontotemporal dementia related to C9orf72 repeat expansion. Cogn Behav Neurol 32(2):120&#x2013;123</Citation><ArticleIdList><ArticleId IdType="pubmed">31205123</ArticleId><ArticleId IdType="doi">10.1097/WNN.0000000000000189</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J, Licata A, Goldhardt O, F&#xf6;rstl H, Yakushew I, Otto M et al (2019) FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry 9(1) [cited 2019 Feb 14]</Citation></Reference><Reference><Citation>Sellami L, Bocchetta M, Masellis M, Cash DM, Dick KM, van Swieten J et al (2018) Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three Main forms of genetic frontotemporal dementia in the GENFI cohort. JAD 13:1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180053</ArticleId></ArticleIdList></Reference><Reference><Citation>Caverzasi E, Battistella G, Chu SA, Rosen H, Zanto TP, Karydas A et al (2019) Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. J Neurol Neurosurg Psychiatry 90(9):1005&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="pubmed">31079065</ArticleId><ArticleId IdType="pmc">6820159</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2018-320265</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson A, Pribadi M, Chowdari K, Clifton S, Wood J, Miller BL et al (2016) C9orf72 repeat expansions that cause frontotemporal dementia are detectable among patients with psychosis. Psychiatry Res 235:200&#x2013;202</Citation><ArticleIdList><ArticleId IdType="pubmed">26723138</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2015.12.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY et al (2019) Genetic screen in a large series of patients with primary progressive aphasia. Alzheimers Dement 15(4):553&#x2013;560</Citation><ArticleIdList><ArticleId IdType="pubmed">30599136</ArticleId><ArticleId IdType="pmc">6480353</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.10.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Grinberg Y, Moreno D, Sato C, Bilbao JM et al (2012) Investigation of C9orf72 in 4 neurodegenerative disorders. Arch Neurol 69(12):1583</Citation><ArticleIdList><ArticleId IdType="pubmed">22964832</ArticleId><ArticleId IdType="pmc">4005900</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2012.2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L, Sagot C, Wallon D, Hannequin D, Payoux P, Nemmi F et al (2014) A case of Logopenic primary progressive aphasia with C9ORF72 expansion and cortical Florbetapir binding. JAD 42(2):413&#x2013;420</Citation><ArticleIdList><ArticleId IdType="pubmed">24898647</ArticleId><ArticleId IdType="doi">10.3233/JAD-140222</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan EP, Baker MC, Perkerson RB, Duffy JR, Strand EA, Whitwell JL et al (2015) Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia. Dement Geriatr Cogn Disord 39(5&#x2013;6):281&#x2013;286</Citation><ArticleIdList><ArticleId IdType="pubmed">25765123</ArticleId><ArticleId IdType="pmc">4879710</ArticleId><ArticleId IdType="doi">10.1159/000375299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallon D, Rovelet-Lecrux A, Deramecourt V, Pariente J, Auriacombe S, Le Ber I et al (2012) Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer&#x2019;s disease cerebrospinal fluid biomarkers. JAD 32(1):19&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">22766732</ArticleId><ArticleId IdType="doi">10.3233/JAD-2012-120877</ArticleId><ArticleId IdType="pmc">22766732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Van Cauwenberghe C, Bettens K, Gijselinck I, van der Zee J, Engelborghs S et al (2013) C9orf72 G4C2 repeat expansions in Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging 34(6):1712.e1&#x2013;1712.e7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K et al (2013) C9orf72 Hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 70(6):736</Citation><ArticleIdList><ArticleId IdType="pubmed">23588422</ArticleId><ArticleId IdType="pmc">3681841</ArticleId><ArticleId IdType="doi">10.1001/2013.jamaneurol.537</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Bieniek KF, Banks Greenberg M, DeJesus-Hernandez M, Rutherford NJ, van Blitterswijk M et al (2013) Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathol 126(4):545&#x2013;554</Citation><ArticleIdList><ArticleId IdType="pubmed">23922030</ArticleId><ArticleId IdType="pmc">3926101</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1161-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O et al (2012) Repeat expansion in C9ORF72 in Alzheimer&#x2019;s disease. N Engl J Med 366(3):283&#x2013;284</Citation><ArticleIdList><ArticleId IdType="pubmed">22216764</ArticleId><ArticleId IdType="pmc">3513272</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1113592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY et al (2020) Genetic screening of a large series of north American sporadic and familial frontotemporal dementia cases. Alzheimers Dement 16(1):118&#x2013;130</Citation><ArticleIdList><ArticleId IdType="pubmed">31914217</ArticleId><ArticleId IdType="pmc">7199807</ArticleId><ArticleId IdType="doi">10.1002/alz.12011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H et al (2012) The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 135(3):723&#x2013;735</Citation><ArticleIdList><ArticleId IdType="pubmed">22300876</ArticleId><ArticleId IdType="doi">10.1093/brain/awr353</ArticleId></ArticleIdList></Reference><Reference><Citation>Annan M, Beaufils &#xc9;, Viola U-C, Vourc&#x2019;h P, Hommet C, Mondon K (2013) Idiopathic Parkinson&#x2019;s disease phenotype related to C9ORF72 repeat expansions: contribution of the neuropsychological assessment. BMC Res Notes 6(1):343</Citation><ArticleIdList><ArticleId IdType="pubmed">23987827</ArticleId><ArticleId IdType="pmc">3765963</ArticleId><ArticleId IdType="doi">10.1186/1756-0500-6-343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Frolov A, Highley JR, Charlesworth G, Kirby J, Milano A et al (2013) C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study. Neurology 81(9):808&#x2013;811</Citation><ArticleIdList><ArticleId IdType="pubmed">23884045</ArticleId><ArticleId IdType="pmc">3908460</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182a2cc38</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinaris T, Houlden H (2018) C9orf72 and its relevance in parkinsonism and movement disorders: a comprehensive review of the literature. Mov Disord Clin Pract 5(6):575&#x2013;585</Citation><ArticleIdList><ArticleId IdType="pubmed">30637277</ArticleId><ArticleId IdType="pmc">6277362</ArticleId><ArticleId IdType="doi">10.1002/mdc3.12677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, Le Ber I, Condroyer C, Broussolle E, Gabelle A, Thobois S et al (2013) C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 136(2):385&#x2013;391</Citation><ArticleIdList><ArticleId IdType="pubmed">23413259</ArticleId><ArticleId IdType="pmc">3984141</ArticleId><ArticleId IdType="doi">10.1093/brain/aws357</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Rayaprolu S, Soto-Ortolaza AI, Rutherford NJ, Heckman MG, Traynor S et al (2013) Analysis of the C9orf72 repeat in Parkinson&#x2019;s disease, essential tremor and restless legs syndrome. Parkinsonism Relat Disord 19(2):198&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">23084342</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2012.09.013</ArticleId><ArticleId IdType="pmc">23084342</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, Noreau A, Rochefort D, Paquin-Lanthier G, Gauthier MT, Provencher P et al (2013) Investigation of C9orf72 repeat expansions in Parkinson&#x2019;s disease. Neurobiol Aging 34(6):1710.e7&#x2013;1710.e9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Inchausti V, Beecham GW, Wang L, Dickson DW, Trojanowski JQ et al (2014) Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson&#x2019;s disease. Mov Disord 29(6):827&#x2013;830</Citation><ArticleIdList><ArticleId IdType="pubmed">24573903</ArticleId><ArticleId IdType="pmc">4022044</ArticleId><ArticleId IdType="doi">10.1002/mds.25838</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannas A, Solla P, Borghero G, Floris GL, Chio A, Mascia MM et al (2015) C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson&#x2019;s disease complicated by psychosis or dementia in a Sardinian population. J Neurol 262(11):2498&#x2013;2503</Citation><ArticleIdList><ArticleId IdType="pubmed">26275564</ArticleId><ArticleId IdType="doi">10.1007/s00415-015-7873-6</ArticleId><ArticleId IdType="pmc">26275564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B et al (2016) C9ORF72 repeat expansions in Chinese patients with Parkinson&#x2019;s disease and multiple system atrophy. J Neural Transm 123(11):1341&#x2013;1345</Citation><ArticleIdList><ArticleId IdType="pubmed">27473499</ArticleId><ArticleId IdType="doi">10.1007/s00702-016-1598-2</ArticleId><ArticleId IdType="pmc">27473499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Bademci G, Kohli MM, Beecham GW, Wang L, Young JI et al (2013) C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Ann Hum Genet 77(5):351&#x2013;363</Citation><ArticleIdList><ArticleId IdType="pubmed">23845100</ArticleId><ArticleId IdType="pmc">3815478</ArticleId><ArticleId IdType="doi">10.1111/ahg.12033</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S et al (2014) Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology 83(21):1906&#x2013;1913</Citation><ArticleIdList><ArticleId IdType="pubmed">25326098</ArticleId><ArticleId IdType="pmc">4248456</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist S, Duno M, Batbayli M, Puschmann A, Braendgaard H, Mardosiene S et al (2013) Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 83(3):279&#x2013;283</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId><ArticleId IdType="doi">10.1111/j.1399-0004.2012.01903.x</ArticleId><ArticleId IdType="pmc">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Quinzii C, Dunning-Broadbent J, Waters C, Mitsumoto H, Brannagan TH et al (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with Hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71(6):771</Citation><ArticleIdList><ArticleId IdType="pubmed">24733620</ArticleId><ArticleId IdType="pmc">4051831</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.5762</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottlaender LV, Polke JM, Ling H, MacDoanld ND, Tucci A, Nanji T et al (2015) The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiol Aging 36(2):1221.e1&#x2013;1221.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.08.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T et al (2014) C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82(4):292&#x2013;299</Citation><ArticleIdList><ArticleId IdType="pubmed">24363131</ArticleId><ArticleId IdType="pmc">3929197</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosti&#x107; VS, Dobri&#x10d;i&#x107; V, Stankovi&#x107; I, Rali&#x107; V, Stefanova E (2014) C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome. J Neurol 261(10):1917&#x2013;1921</Citation><ArticleIdList><ArticleId IdType="pubmed">25034271</ArticleId><ArticleId IdType="doi">10.1007/s00415-014-7430-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida CM, Butz ML, Lundquist PA, Dawson DB (2018) C9orf72 repeat expansion frequency among patients with Huntington disease genetic testing. Neurodegener Dis 18(5&#x2013;6):239&#x2013;253</Citation><ArticleIdList><ArticleId IdType="pubmed">30336474</ArticleId><ArticleId IdType="doi">10.1159/000492499</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Vourc&#x2019;h P, Guennoc A-M, Del Mar Amador M, Blasco H, Andres C et al (2016) Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotroph Lat Scl Fr 17(3&#x2013;4):301&#x2013;303</Citation></Reference><Reference><Citation>Zhang M, Xi Z, Misquitta K, Sato C, Moreno D, Liang Y et al (2017) C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism. Mov Disord 32(1):158&#x2013;162</Citation><ArticleIdList><ArticleId IdType="pubmed">28124431</ArticleId><ArticleId IdType="doi">10.1002/mds.26841</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni M, Farris R, Solla P, Mascia MM, Marrosu F, Cannas A (2017) C9ORF72 intermediate repeat expansion in a patient with psychiatric disorders and progressive cerebellar Ataxia. Neurologist 22(6):245&#x2013;246</Citation><ArticleIdList><ArticleId IdType="pubmed">29095328</ArticleId><ArticleId IdType="doi">10.1097/NRL.0000000000000147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel BL, Pribadi M, Pi S, Perlman SL, Geschwind DH, Coppola G (2012) C9ORF72 expansion is not a significant cause of sporadic spinocerebellar ataxia. Mov Disord 27(14):1835&#x2013;1836</Citation><ArticleIdList><ArticleId IdType="pmc">3536912</ArticleId><ArticleId IdType="doi">10.1002/mds.25245</ArticleId><ArticleId IdType="pubmed">3536912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao C-T, Tsai P-C, Liao Y-C, Lee Y-C, Soong B-W (2014) C9ORF72 repeat expansion is not a significant cause of late onset cerebellar ataxia syndrome. J Neurol Sci 347(1&#x2013;2):322&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">25467142</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2014.10.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-Martin S et al (2019) C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol Commun 7(1):115</Citation><ArticleIdList><ArticleId IdType="pubmed">31315673</ArticleId><ArticleId IdType="pmc">6637621</ArticleId><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme T, Guerreiro R, Bras J (2018) The genetics of dementia with Lewy bodies: current understanding and future directions. Curr Neurol Neurosci Rep 18(10):67</Citation><ArticleIdList><ArticleId IdType="pubmed">30097731</ArticleId><ArticleId IdType="pmc">6097049</ArticleId><ArticleId IdType="doi">10.1007/s11910-018-0874-y</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN et al (2013) Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 12(10):978&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pubmed">24011653</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C (2017) Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev 44:117&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pubmed">28319737</ArticleId><ArticleId IdType="doi">10.1016/j.gde.2017.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F et al (2019) Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging 74:234.e1&#x2013;234.e8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JL, Finch NA, Baker MC, Kachergus JM, DeJesus-Hernandez M, Pereira K et al (2020) Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener 15(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">32000838</ArticleId><ArticleId IdType="pmc">6993399</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-0359-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC et al (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 127(3):407&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pubmed">24442578</ArticleId><ArticleId IdType="pmc">4003885</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1239-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-P&#xe9;choux S, Camuzat A et al (2014) Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol Aging 35(11):2658.e1&#x2013;2658.e5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.06.023</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Wojtas A, Heckman MG, Diehl NN, Baker MC et al (2014) Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener 9(1):38</Citation><ArticleIdList><ArticleId IdType="pubmed">25239657</ArticleId><ArticleId IdType="pmc">4190282</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-9-38</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U et al (2018) A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain 141(10):2895&#x2013;2907</Citation><ArticleIdList><ArticleId IdType="pubmed">30252044</ArticleId><ArticleId IdType="pmc">6158742</ArticleId><ArticleId IdType="doi">10.1093/brain/awy238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R et al (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130(1):77&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">25943890</ArticleId><ArticleId IdType="pmc">4470809</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Baker MC, DeJesus-Hernandez M, Ghidoni R, Benussi L, Finger E et al (2013) C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 81(15):1332&#x2013;1341</Citation><ArticleIdList><ArticleId IdType="pubmed">24027057</ArticleId><ArticleId IdType="pmc">3806926</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182a8250c</ArticleId></ArticleIdList></Reference><Reference><Citation>Testi S, Tamburin S, Zanette G, Fabrizi GM (2015) Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. JAD 44(1):49&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">25182743</ArticleId><ArticleId IdType="doi">10.3233/JAD-141794</ArticleId><ArticleId IdType="pmc">25182743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>